Physician profile
Robert Boynton
NPI 1841238656
$6,349.52
in general payments reported to CMS, 2019-2025
37 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $218 · 2021: $337 · 2022: $869 · 2023: $1,284 · 2024: $1,345 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $61.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.75 |
| Education | $61.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.22 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Capsovision, INC. | $800.00 | 2019 | |
| Janssen Biotech, INC. | $519.54 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $453.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.08 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $197.51 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $194.80 | 2019-2022 | |
| Celgene Corporation | $192.19 | 2021-2024 | Zeposia |
| Pfizer INC. | $178.09 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $147.65 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $143.01 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $141.99 | 2019-2025 | Injectafer |
| Lilly USA, LLC | $127.07 | 2024-2025 | Omvoh |
| Genzyme Corporation | $125.84 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $114.35 | 2019-2024 | Ocaliva |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boynton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.